A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in addition to a favourable safety profile and high in vivo persistence of CAR30+ cells. The results of this pioneering study in Europe have been published in the prestigious journal Blood. The study has been led by Dr. Javier Briones, group leader at the IR San Pau and the Josep Carreras Institute and…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply